Endothelial protective effect of pitavastatin
https://doi.org/10.15829/1728-8800-2023-3671
EDN: PBVGNY
Abstract
The article discusses topical issues of modern concepts of aging, including vascular aging due to the progression of endothelial dysfunction, atherogenesis, chronic and acute cardiovascular atherosclerosis-related diseases. Modern potential of anti-aging therapy aimed at slowing the progression of vascular aging and endothelial dysfunction are reflected. A descriptive literature review was carried out based on the analysis of sources from the PubMed, eLibrary databases for the following keywords: endothelium, aging, pitavastatin, anti-aging effect (endothelium, aging, pitavastatin, anti-aging effect). Based on a review, the role of pitavastatin is shown not only as an effective cholesterol-lowering drug, but also as an agent with a large number of proven pleiotropic effects, as well as an optimal safety profile and a low risk of side effects and drug interactions. On the example of a case, the potential of high-intensity lipid-lowering therapy with the use of pitavastatin in a comorbid patient are illustrated.
About the Authors
A. S. Berns
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
V. V. Kashtalap
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
References
1. López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039.
2. Vlasov TD, Nesterovich II, Szymanski DA. Endothelial dysfunction: from private to general. A return to the "old paradigm"? Regional circulation and microcirculation. 2019;18(2):19-27. (In Russ.) doi:10.24884/1682-6655-2019-18-2-19-27.
3. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6. doi:10.1038/288373a0.
4. Sadulaeva IA, Khalikova LF, Medvedeva EG, et al. Relationship of endothelial dysfunction markers with blood pressure control in hypertension in obese patients. Effective pharmacotherapy. 2022;18(41):6-11. (In Russ.) doi:10.33978/2307-3586-2022-18-41-6-11.
5. Danielli JF. Capillary permeability and oedema in the perfused frog. J Physiol. 1940;98(1):109-29. doi:10.1113/jphysiol.1940.sp003837.
6. Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red. Fed Proc. 1966;25(6):1773-83.
7. Schött U, Solomon C, Fries D, et al. The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review. Scand J Trauma Resusc Emerg Med. 2016;24:48. doi:10.1186/s13049-016-0239-y.
8. Alphonsus CS, Rodseth RN. The endothelial glycocalyx: a review of the vascular barrier. Anaesthesia. 2014;69(7):777-84. doi:10.1111/anae.12661.
9. Kolarova H, Ambruzova B, Svihalkova-Sindlerova L, et al. Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediators Inflamm. 2014:694312. doi:10.1155/2014/694312.
10. Becker BF, Jacob M, Leipert S, et al. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015;80(3):389-402. doi:10.1111/bcp.12629.
11. Yen W, Cai B, Yang J, et al. Endothelial surface glycocalyx can regulate flow-induced nitric oxide production in microvessels in vivo. PLoS One. 2015;10(1):e0117133. doi:10.1371/journal.pone.0117133.
12. Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345-59. doi:10.1007/s00424-007-0212-8.
13. Bleakley C, Hamilton PK, Pumb R, et al. Endothelial Function in Hypertension: Victim or Culprit? The Journal of Clinical Hypertension. 2015;17(8):651-4. doi:10.1111/jch.12546.
14. Bernatova I. Endothelial Dysfunction in Experimental Models of Arterial Hypertension: Cause or Consequence? BioMed Research International. 2014;(2014):1-14. doi:10.1155/2014/598271.
15. Liu X, Ma D, Zheng S, et al. The roles of nitric oxide and hydrogen sulfide in the anti-atherosclerotic effect of atorvastatin. J Cardiovasc Med. 2015;16(1):22-8. doi:10.2459/JCM.0000000000000012.
16. Tatsumi K, Mackman N. Tissue Factor and Atherothrombosis. J Atheroscler Thromb. 2015;22(6):543-9. doi:10.5551/jat.30940.
17. Torimoto K, Okada Y, Tanaka Y. Type 2 Diabetes and Vascular Endothelial Dysfunction. J UOEH. 2018;40(1):65-75. doi:10.7888/juoeh.40.65.
18. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi:10.1186/s12933-018-0763-3.
19. Zhou Y, Wang Y, Wang G, et al. Association Between Statin Use and Progression of Arterial Stiffness Among Adults With High Atherosclerotic Risk. JAMA Netw Open. 2022;5(6):e2218323. doi:10.1001/jamanetworkopen.2022.18323.
20. Katapano A, Kukharchuk VV, Sergienko IV, et al. Pitavastatin is a modern statin for the correction of dyslipidemia and the risk of cardiovascular complications. Expert Council Resolution. Ateroskleroz i dislipidemii. 2017;2:104-6. (In Russ.) EDN: YTZWYZ.
21. Weng TC, Yang YH, Lin SJ, et al. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51. doi:10.1111/j.1365-2710.2009.01085.x.
22. Warita S, Kawasaki M, Tanaka R, et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years follow-up. Circ J. 2012;76(12):2755-62. doi:10.1253/circj.cj-12-0722.
23. Ford I, Murray H, McCowan C, et al. Long-Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation. 2016;133:1073-80. doi:10.1161/CIRCULATIONAHA.115.019014.
24. Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131-49. doi:10.1002/pds.4020.
25. Kawai Y, Sato-Ishida R, Motoyama A, et al. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug Des Devel Ther. 2011;5:283-97. doi:10.2147/DDDT.S13492.
26. Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler. 2011;12:285-8. doi:10.1016/S1567-5688(11)70888-1.
27. Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2:134-40. doi:10.1007/s13340-011-0032-0.
28. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089-101. doi:10.1016/j.clinthera.2008.05.017.
29. Arai H, Hiro T, Kimura T, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome — sub-analysis of JAPAN-ACS study. J Atheroscler Thromb. 2010;17(10):1096-107. doi:10.5551/jat.5660.
30. Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39-45. doi:10.1016/j.thromres.2007.08.013.
31. Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136-8. doi:10.1016/j.ijcard.2007.01.040.
32. Markle RA, Han J, Summers BD, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem. 2003;90:23-32. doi:10.1002/jcb.10602.
33. Wang J, Tokoro T, Matsui K, et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci. 2005;76(19):2257-68. doi:10.1016/j.lfs.2004.12.003.
34. Ohbayashi H, Miyazawa C, Miyamoto K. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb. 2009;16(4):490-500. doi:10.5551/jat.no613.
35. Sedykh DYu, Khryachkova ON, Kashtalap VV, et al. Treatment for dyslipidemia in comorbid patients in real clinical practice: potentialities of pitavastatin. Russian Medical Inquiry. 2021;5(4):218-24. (In Russ.) doi:10.32364/2587-6821-2021-5-4-218-224.
36. Srichatrapimuk S, Wongsa A, Sungkanuparph S, et al. Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study. AIDS Res Ther. 2023;20(1):13. doi:10.1186/s12981-023-00506-2.
37. Troitskaya EA, Velmakin SV, Kobalava ZD. Concept of vascular age: new tool in cardiovascular risk assessment. Arterial Hypertension. 2017;23(2):160-71. (In Russ.) doi:10.18705/1607-419Х-2017-23-2-160-171.
Supplementary files
What is already known about the subject?
- It is known that endothelial dysfunction is a significant marker not only of cardiovascular risk, but also of general aging. At the same time, endo-thelial dysfunction is accompanied by a number of other pathological mechanisms: hyperaggregation, hypercoagulation, progression of atherosclerosis.
What might this study add?
- Numerous favorable biochemical and clinical effects of pitavastatin are presented — lipid-lowering, endothelium-protective, antiplatelet, nephroprotective, which lead to a total anti-aging effect, which should be used in clinical practice.
- The case demonstrates the high efficacy of pitavastatin in a comorbid patient to control dyslipidemia, slow down the progression of atherosclerosis and improve endothelial function (anti-aging effect).
Review
For citations:
Berns A.S., Kashtalap V.V. Endothelial protective effect of pitavastatin. Cardiovascular Therapy and Prevention. 2023;22(8):3671. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3671. EDN: PBVGNY
Views:
4255
Email this article 
